Biodesix, Inc. (BDSX)

Market Cap	97.81M
Revenue (ttm)	71.32M
Net Income (ttm)	-42.93M
Shares Out	145.98M
EPS (ttm)	-0.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	154,974
Open	0.7200
Previous Close	0.7128
Day's Range	0.6700 - 0.7319
52-Week Range	0.6350 - 2.0400
Beta	1.10
Analysts	Strong Buy
Price Target	2.93 (+337.31%)
Earnings Date	Mar 3, 2025

About BDSX

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, together marketed as part of IQLung testing strategy, which are used i...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 28, 2020
• Employees: 273
• Stock Exchange: NASDAQ
• Ticker Symbol: BDSX
• Website: https://www.biodesix.com

Financial Performance

In 2024, Biodesix's revenue was $71.32 million, an increase of 45.30% compared to the previous year's $49.09 million. Losses were -$42.93 million, -17.67% less than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for BDSX stock is "Strong Buy." The 12-month stock price forecast is $2.93, which is an increase of 337.31% from the latest price.

Price Target

$2.93

(337.31% upside)

Analyst Consensus: Strong Buy